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performed. RESULTS: Incremental cost effectiveness ratios were calculated for
each anti-TNF in comparison to methotrexate. Infliximab is dominated in almost
all scenarios, being more costly and less effective. Etanercept and adalimumab are
the most effective options and most costly. Golimumab appears less effective and
less costly. Sensitivity analysis around utility measure and HAQ improvement as-
sumptions indicate that these are key drivers to the estimates. CONCLUSIONS:
This CUA focuses on novel methods for data inputs estimation. Both Bayesian and
frequentist methods are employed in order to validate the sub models used. The
outputs from the cost utility model show that etanercept and adalimumab appear
most effective on the cost effectiveness plane. However they are also more costly
than both golimumab and certolizumab pegol.
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OBJECTIVES: Falls/Slips cases injured with over the level two and their medical
costs for a year of 2008 at 3 teaching hospitals are explored. METHODS: There are
2559, 1394, and 4086 incident reports in 2008 collected at St. Mary’s Hospital, Shi-
mane University Hospital, and Kyoto University Hospital, Japan. Their reports in-
clude 565, 399, and 561 cases for Falls/Slips. The cases are classified 264, 176, and
306 cases with level 2, and 89, 32, and 82 cases with level 3a, and 8, 3, and 5 cases
with level 3b, respectively. We explored 963 cases with over level 2 in order to
calculate additional medical costs by using their own administrative profiling data.
RESULTS: According to the injury level, average AMCs are 108 at SMH, 175 at SUH
and, 72 USD at KUH (level 2), respectively. Similarly, Average AMCs are 122, 223, and
97 USD (level 3a), and 1,431, 7,745 and 33,357 USD (level 3b), respectively.With
regard to clinical services, AMC with diagnostic imaging is the highest (10,118 USD,
SMH; 14,090 USD, SUH), but AMC with surgery/treatment is the highest at KUH,
92,115 USD. AMC with surgery/treatment is 6900 USD at SMH, and 8879 USD at SUH,
AMC with iv/div is 1275 USD at SMH and 1818 USD at SUH, AMC with laboratory
examination is 674 USD at SMH, and 899 USD at SUH, and AMC with drug admin-
istration is 455 USD at SMH and 318 USD at SUH. By contrast, AMCs at KUH are
11578 USD (imaging), 11290 USD (examination), 3372 USD (drug administration),
and 714 USD (iv/div), because AMC with level 3b and over is the highest by clinical
services. CONCLUSIONS: Therefore, Hospital administrators and policy makers
have to take appropriate measures to prevent patients from Falls/Slips and save
money, because this amount is not overlooked.
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OBJECTIVES: To assess the impact of ankylosing spondylitis (AS) on work produc-
tivity, to determine factors influencing work productivity and to estimate produc-
tivity costs incurred by AS in the Czech Republic. METHODS: A questionnaire in-
cluding Work Productivity and Activity Impairment Questionnaire (WPAI:AS),
Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) were filled out by 230 patients with AS in productive age.
The interdependence between HAQ, BASDAI, disease duration, age and WPAI:AS
scores were described by Spearman=s rank correlation coefficient. We have ana-
lyzed differences between work-active and all patients (work-active  disable)
groups, effect of biological treatment and education level on work productivity.
Productivity costs were calculated by friction cost approach (FCA) using friction
period of 130 work-days and average monthly gross income as denominator.
RESULTS: Average patients= age was 49.3 years (22-61) and average disease dura-
tion 18.0 years. Mean HAQ and BASDAI were 0.99 and 4.43, respectively. We re-
ported significantly greater loss in work productivity (p-value0,001) and daily
activities impairment (p-value0,001) for disable patients in compare to work-
active patients, differences were by 35.6% and 19.6%, respectively. AS in work-
active patients group was associated with 40.7% reduction in work productivity and
40.3% reduction in daily activities. Work-active patients group revealed signifi-
cantly lower age (p-value0,001), lower BASDAI (p-value0,001) and lower HAQ
(p-value0,001). Work absenteeism was weakly correlated with BASDAI and HAQ.
Work presenteeism and overall work impairment were moderately correlated with
BASDAI and HAQ, whereas impairment of daily activities was strongly correlated
with all four WPAI domains. Average annual productivity costs per one patient
were €2923 in all patients group. CONCLUSIONS: HAQ, BASDAI and age signifi-
cantly influence patients’ productivity. Patients on biologics had lower impairment
of daily activities and work productivity and revealed lower HAQ and BASDAI as
well. Average annual productivity costs per one patient were €2923.
Muscular-Skeletal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
PMS54
THE CLINICAL AND ECONOMIC BURDEN OF POOR ADHERENCE WITH
OSTEOPOROSIS MEDICATIONS IN IRELAND
Hiligsmann M1, Mcgowan B2, Bennett K2, Barry M3, Reginster JY4
1Maastricht University, Maastricht, The Netherlands, 2Trinity Centre for Health Sciences, Dublin,
Ireland, 3National Centre for Pharmacoeconomics, Dublin, Ireland, 4University of Liège, Liège,
Belgium
OBJECTIVES: The economic impact of therapeutic non-adherence has been rarely
examined in chronic diseases. This study aims to estimate the impact of non-
adherence with osteoporosis medications on clinical and economic outcomes and
to evaluate the economic value of improving patient compliance using hypotheti-
cal interventions. METHODS: A previously validated Markov microsimulation
model was adapted to the Irish setting to estimate long-term costs and outcomes
(fractures, life years and quality-adjusted life-year (QALY)) for three adherence
scenarios: no treatment, real-world adherence and full adherence over 3 years. The
real-world adherence employed compliance and persistence data from the Irish
HSE-PCRS pharmacy claims database. The number of fractures associated with
poor adherence and the incremental cost per QALY gained between the adherence
scenarios was estimated. We also investigated the cost-effectiveness of hypothet-
ical adherence-enhancing interventions according to their cost and effect on ad-
herence (improvements between 10% and 50%). RESULTS: The number of fractures
prevented and the QALY gain obtained at real-world adherence levels represented
only 57% and 56% of those expected with full adherence, respectively. Over 3 years,
a total number of 3,340 fractures including 1,271 at the hip were estimated to be
associated with non-adherence, resulting in a loss of 3,044 QALYs. The costs per
QALY gained of real-world adherence and of full adherence compared with no
treatment were estimated at €11,834 and €6,341. An intervention to improve ad-
herence by 25% would result in an ICER of €11,392/QALY and €54,182/QALY if the
intervention cost an additional €50 and €100 per year, respectively. CONCLUSIONS:
Poor adherence with osteoporosis medications results in a 50% reduction in the
potential benefits observed in clinical trials and a doubling of the cost per QALY
gained from these medications. Depending on their costs and outcomes, adher-
ence-enhancing interventions have the potential to be an attractive approach to
improve the allocation of resources.
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OBJECTIVES: The present study investigates the treatment persistence of osteopo-
rosis and assesses its impacts on the risk of fractures among women in Taiwan.
METHODS: This is a retrospective cohort study design. Patients who filled prescrip-
tions of alendronate, ibandrobate, risedronate, zoledronate, raloxifene or teripa-
ratide during 2005-2009 were retrieved from the National Health Insurance Re-
search database. Non-persistence was defined when the patients did not refill
prescription within 30 days after the previous osteoporosis prescriptions. Relative
risks of fracture incidence within 3 years after the initial prescription date in four
persistence groups (30 days, 1 month-1 year, 1-2 years, 2-3 years) were evaluated
based upon survival analysis. RESULTS: A total of 1,287,253 patients were included
and followed during the study period of 2005-2009. The overall persistence rates
among patients with osteoporosis drug treatment were 37%, 29%, 21%, and 9% after
1, 2, 3, and 4 years, respectively. Risks of fractures were higher in the lower persis-
tence group (HR 0.87, p0.092 in 1 month-1 year persistence; HR 0.61, p0.001 in 2-3
years persistence). CONCLUSIONS: The relatively high non-persistence rates
among patients with osteoporosis treatment and the significant negative associa-
tion between treatment persistence and fracture incidence indicates potential
cost-savings and health gains are substantial if improvement in the treatment
persistence can be achieved.
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OBJECTIVES: To study self-estimates of rheumatoid arthritis (RA) patients regard-
ing their future health related quality of life and to assess the acceptability of
different health problems at certain stages of life. METHODS: A cross-sectional
survey was performed in 12 rheumatology centres. RA patients initiating first bio-
logical therapy were involved. Disease activity (DAS28) was registered, health sta-
tus (EQ-5D) and functional disability (HAQ-DI) questionnaires were applied. Partic-
ipants were asked to indicate the health status they expect in 3 months time and
for ages 60, 70 and 80 years, using the health problem descriptions of the EQ-5D.
Concerns regarding ”some” and ”severe problems” in the dimensions of the EQ-5D
and HAQ-DI were surveyed by age (acceptable from age 30, 40, 50, 60, 70, 80 or
never). RESULTS: Altogether 116 patients (87.4% females) were involved, mean
(SD): age 52.3 (11.7) years, disease duration 9.3 (8.3) years, DAS28 6.17 (0.89), EQ-5D
score 0.348 (0.358), HAQ-DI 1.476 (0.653). Expected status after 3 months: EQ-5D
0.759 (0.270), HAQ-DI 0.648 (0.593). Patient expect to have significantly worse EQ-5D
scores at ages 60, 70 and 80 than the actual age specific general population has,
mean (SD): 0.438 (0.373) versus 0.728 (0.012); 0.240 (0.406) versus 0.682 (0.016) and
0.070 (0.411) versus 0.615 (0.024), respectively. The majority (26.3%-39.5%) pointed
that ”some problems” in five dimensions of the EQ-5D are acceptable from age 70.
The ”severe problems” level was rejected as never acceptable (54.3%-68.0%) except
the ”usual activities” dimension wherat extreme problems were accepted from age
80 by 47.1%. Similar outcomes were found with the HAQ-DI. CONCLUSIONS: RA
patients initiating biological drug expect quick improvement but prognosticate
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sharp health deterioration with age. Nevertheless, moderate health problems are
considered as acceptable in advanced ages. These findings intend to support com-
pliance research and health gain valuations.
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OBJECTIVES: Sleep issues have been reported by patients with rheumatoid arthri-
tis (RA) and recently recommended as a clinical trial endpoint. The objective of this
study was to conduct a quantitative validation of the sleep disturbance and sleep
adequacy subscales of the 1-week recall Medical Outcomes Study Sleep Scale
(MOS-SS) in patients with RA. METHODS: Participants with self-reported RA were
recruited via newspaper or online advertisements in two regions of the US. Partic-
ipants completed measures in-person, then completed a one-week retest via mail.
Internal consistency of the MOS-SS subscales was evaluated using Cronbach’s ;
test-retest reliability was assessed using Intraclass Correlation Coefficient (ICC).
Pearson’s correlation coefficient was calculated to assess convergent validity of
MOS-SS 1-week subscales with a Sleep Numeric Rating Scale (NRS). Known-groups
validity was assessed using ANOVA to compare MOS-SS mean subscale scores with
self-reported RA severity (mild, moderate, severe) and general health (very good,
good, fair, poor). RESULTS: Participants (N50) were 76% female, 72% White, mean
age (SD) 49.4 (13.2) years and mean disease duration (SD) 13.7 (12.0) years. Cron-
bach’s  for sleep disturbance and adequacy subscales were 0.73 and 0.71, respec-
tively. Mean sleep disturbance and adequacy subscale scores were 47.1 and 34.0 at
baseline, 47.3 and 32.0 at 1-week follow-up (ICC0.78 and 0.75), respectively. Cor-
relations of the sleep disturbance and adequacy subscales with the Sleep NRS were
r0.43 (p0.002) and r0.45 (p0.001), respectively. Mean sleep disturbance and
adequacy subscale scores across RA severity and health status groups trended as
hypothesized but were not significantly different. CONCLUSIONS: The MOS-SS
sleep disturbance and sleep adequacy subscales demonstrated good internal con-
sistency and test-retest reliability, modest convergent validity, and trended but did
not significantly discriminate based on RA severity or general health. Further psy-
chometric analysis in a larger sample of RA patients is needed to determine if these
subscales could be useful in clinical trials.
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OBJECTIVES: Fatigue has been reported by patients as an important symptom of
rheumatoid arthritis (RA) and recommended for measurement in clinical trials.
The objective was to evaluate the validity of, ‘WORST level of fatigue (weariness,
tiredness) during the past 24 hours,’ item of the Brief Fatigue Inventory (BFI Q3) in
a sample of US patients with self-reported RA. METHODS: 50 adults with RA were
recruited to complete questionnaires at baseline and one week later. Internal con-
sistency reliability of the BFI fatigue severity subscale (questions 1-3) was evalu-
ated using Cronbach’s . BFI Q3 was assessed using Intraclass Correlation Coeffi-
cient (ICC) for test-retest reliability; Pearson’s correlation coefficient for convergent
validity with BFI fatigue severity subscale and Multidimensional Assessment of
Fatigue (MAF) global score; and analysis of variance for known-groups discriminant
validity with self-reported RA severity (mild, moderate, severe) and general health
(very good, good, fair, poor). RESULTS: Participants were 76% female, 72% Cauca-
sian, mean age (SD) 49.4(13.2) years and mean disease duration 13.7(12.0) years.
Mean BFI Q3 score was 7.3(1.9) at initial and 6.8 (2.3) at retest; ICC0.58. Correlation
with fatigue severity subscale and MAF were r0.79(p.001) and r.02(p.92), re-
spectively. Cronbach’s  for severity subscale 0.84. Mean BFI Q3 scores were 6.0,
7.1 and 7.8 (p.36) and poor general health were 5.6, 7.0, 7.9, and 9.0 (p.01),
respectively. CONCLUSIONS: In a small sample of patients with RA, assessment of
worst fatigue severity as measured by BFI Q3 demonstrated validity. Discrimina-
tion based on RA severity was not significant, possibly due to low study power,
however trended in the hypothesized direction. Test-retest reliability was low but
acceptable, and expected due potentially to the episodic nature of fatigue. Further
validation of the BFI Q3 in a larger sample is needed to confirm these findings that
the measure is useful in the context of RA clinical trials.
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OBJECTIVES: Osteoarthritis (OA) has significant patient and economic burden. De-
spite treatments for OA, data on treatment patterns, adequacy of pain relief, and
quality of life are limited. SORT was designed to determine the adequacy of pain
relief, and compare patterns of clinical care and patient reported outcomes (PROs)
in patients with knee OA.METHODS: SORT, a 12-month prospective, observational
study will enroll 1400 participants (across 6 countries) who use oral or topical
analgesics for knee OA symptoms. Participants visiting a primary care physician
must be  50 years old. Clinical history, medications, quality of life and resource
use are collected at baseline and months 1, 3, 6, 9 and 12. Inadequate pain relief
(IPR) was defined as an average Brief Pain Inventory pain score of “moderate or
greater pain” (score 4). This interim assessment reports data from the UK only.
RESULTS: To date, 141 participants from the UK have provided baseline data: 67%
women; median (range) age 68 years (51-90); history of diagnosed knee OA for an
average of 6 years and 68% taking oral pain medication only. Hypertension (52%)
was the most common co-morbidity. IPR was reported by 64% of the cohort at
baseline (90 of 141). Patients reporting IPR and non-IPR were similar in clinical
characteristics (p.05): BMI 31 kg/m2 (20-55), co-existing OA of the hip (16%) &
spine (29%). Participants with IPR (vs. non-IPR) differed in their rating of other PROs:
WOMAC Stiffness (mean: 127 vs. 81, p 0.01); Physical Function (969 vs. 499, p
0.01); SF-12 General Health (fair/poor 42% vs. 12%, p0.01) and satisfaction with
prescribed treatment (less than satisfied 47% vs. 28%, p 0.01). CONCLUSIONS:
With 64% of UK participants reporting IPR at baseline, SORT will provide valuable
insight into current treatment patterns and PROs for individuals with knee OA.
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OBJECTIVES: The patient perspective has become increasingly important in the
field of rheumatology research. Understanding cross-cultural experiences of RA is
helpful when designing clinical trials that include PRO measures. Qualitative data
from this study were used to compare the experiences of patients with RA in the US
and UK. METHODS: Patients with RA in the US and UK who met specific inclusion
and exclusion criteria were recruited; criteria in UK were less restrictive than in the
US. Concept elicitation interviews were conducted and interview transcripts were
analyzed with the aid of ATLAS.ti software to identify concepts and explore inter-
relationships between concepts. Data were collected and analyzed in accordance
with the US FDA’s final guidance on PRO instrument development and validation.
RESULTS:A total of 32 participants were recruited (19 in US; 13 in UK), of which the
majority were female (74% in US; 77% in UK) and White (68% in US; 77% in UK).
Mean age (SD) of the US and UK participants was 65.1 (6.9) and 47.7 (14.7), respec-
tively. Descriptions of RA in both populations were similar and included pain
(n32) and fatigue-like effects of RA (n17), which impacted daily activity and
psychological well-being. Descriptions of pain were similar in US and UK popula-
tions: “dull,” “shooting,” “nagging,” and “gnawing.” The term ”fatigue” was men-
tioned spontaneously by some (n5, 26%) of US participants, and was not men-
tioned spontaneously by any UK participants. The majority of those asked whether
fatigue was a term they would use to describe their symptom affirmed the use of
fatigue (71.4% in US and 90% in UK). CONCLUSIONS: This small, qualitative, study
identified few differences in experiences of RA in US and UK patient populations.
Qualitative research is useful for identifying whether the use of identical PRO mea-
sures is acceptable in multi-national clinical trials.
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OBJECTIVES: To determine the impact of CZP on patient-reported outcomes
(PROs), including fatigue and sleep problems, among patients (pts) with active RA
who participated in the REALISTIC (RA EvALuation In Subjects receiving TNF Inhib-
itor Certolizumab pegol [CZP]) study. METHODS: A total of 1,063 eligible pts were
randomised 4:1 to CZP 400mg at Wks 0, 2 and 4 followed by 200mg every 2 wks or
placebo injection (control) every 2 wks added to current therapy. PROs included
fatigue (Fatigue Assessment Scale [FAS]), sleep quantity and quality (Sleep Problem
Index II domain, Medical Outcomes Study sleep scale [MOS-SPI]), pain (visual ana-
logue scale [VAS]), and pts global assessment of disease activity (PtGA, VAS). The %
of pts reporting minimal clinically important differences (MCIDs) was determined:
1 FAS, 6 MOS-SPI, and 10mm pain-VAS and PtGA. Correlations between PROs
and DAS28 were assessed (Pearson 
, CZP group only). NCT00717236. RESULTS:
Baseline (BL) characteristics were similar for both groups. Significant, meaningful
improvements, compared with BL, in fatigue were reported with CZP vs control
from the first time point at Wk 2 (1.1 vs 0.2; p0.001) to Wk 12 (1.3 vs 0.5;
p0.001). Sleep problems were significantly reduced with CZP vs control from
the first assessment at Wk 6 (7.6 vs 4.8; p0.05) to Wk 12 (7.6 vs 4.2;
p0.01). CZP significantly reduced pain and PtGA from Wk 2 (pain:15.3 vs2.8,
PtGA:14.7 vs2.5; p0.001). At Wk 12, more CZP pts had improvementsMCID
in FAS (56.4% vs 46.2%, p0.01), MOS-SPI (49.7% vs 42.5%, p0.058), pain (59.0%
vs 42.0%, p0.001) and PtGA (59.5% vs 42.5%, p0.001). Correlations between
PROs and DAS28 were moderate (0.3rho0.6). CONCLUSIONS: CZP was associ-
ated with clinically meaningful reductions in fatigue and sleep problems, and im-
provements in pain and PtGA, in a diverse group of RA pts reflecting those seen in
daily clinical practice.
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